1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Adult Malignant Glioma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Adult Malignant Glioma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • August 2018
  • 228 pages
  • ID: 5586950
  • Format: PDF
  • Transparency Market Research
Up to $2949 off Until Apr 20th 2021

Summary

Table of Contents

Adult Malignant Glioma Therapeutics Market - Overview

This report studies the current as well as future prospects of the global adult malignant glioma therapeutics market.Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of malignant glioma therapeutics and new entrants planning to enter the market.

This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global adult malignant glioma therapeutics market regarding leading segments based on type, therapy, and region.

The global adult malignant glioma therapeutics market has been segmented based on type, therapy, and region.In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others.

Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy.The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others.

The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others.

The bottom-up approach for determining the market size was studied using various market indicators obtained from secondary sources, which include population in 2017, prevalence of all types of malignant glioma in major countries, variations in therapy cost across major regions, and approval of therapeutics in specific region.The top-down approach was used to derive the market size for therapy segments, wherein revenues of all publicly listed market players were obtained through secondary sources and analyzed for glioma specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others.

Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research.Moreover, historical year-on-year growth has been taken into consideration while estimating the market size.

The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global adult malignant glioma therapeutics market and could influence it in the near future.Market attractiveness analysis has been provided to explain the intensity of competition in the market across different regions.

The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report.These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global adult malignant glioma therapeutics market.

The report also comprises adult malignant glioma disease overview by type, pipeline analysis, Porter’s Five Forces analysis, overview of epidemiology of glioma, snapshot of disease burden by key region / country, SWOT analysis by key therapies, regulatory scenario, reimbursement scenario, comparative analysis of available therapies & imaging landscape, and key market trends by region.

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.The market size and forecast for each of these regions has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

The report also provides market size and forecast for major countries with each product and distribution channel in the respective regions.A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section.

This section of the report also provides the market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global adult malignant glioma therapeutics market.

Major players operating in the global adult malignant glioma therapeutics market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

The global adult malignant glioma therapeutics market has been segmented as follows:

Global Adult Malignant Glioma Therapeutics Market, by Type
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Others

Global Adult Malignant Glioma Therapeutics Market, by Therapy
Chemotherapy
Temozolomide
Bevacizumab
Carmustine
Others

Targeted Drug Therapy
EGFR Inhibitors
Other Monoclonal Antibodies
Others

Radiation Therapy
Global Adult Malignant Glioma Therapeutics Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

$5795

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Multiple Myeloma Therapeutics Industry

  • $ 5450
  • April 2021
  • 216 pages

Abstract: - Global Multiple Myeloma Therapeutics Market to Reach $27.1 Billion by 2027 - Amid the COVID-19 crisis, the global market for Multiple Myeloma Therapeutics estimated at US$9.9 Billion in ...

  • World
  • China
  • Therapy
  • Cancer
  • Industry analysis

Global Algae Fats Industry $ 4950 April 2021


ref:plp2018

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on